The FDA has authorized an expanded access program that will allow for the use of a recombinant bacillus Calmette-Guerin product.

FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.

ImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an ...

Shares of ImmunityBio Inc. surged 16.4% on Wednesday, marking their best session in over a month, and extended gains in after ...

We recently published a list of 10 Stocks Stand Strong Amid Cautious Market Environment. In this article, we are going to ...

Garmin reported fiscal fourth-quarter 2024 revenue growth of 23% year-on-year to $1.82 billion, beating the analyst consensus estimate of $1.70 billion. The GPS navigation and wearable technology ...

PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling technology, today announced that they will share the latest routine immunization study ...

Well, a global provider of genomic library and multiplexing workflow solutions, today announced the early access availability of the new MosaiXtm Library Prep Kit, designed for demanding applications ...

ImmunityBio (IBRX) announced the U.S. Food and Drug Administration FDA has authorized an expanded access program EAP that will bring a vital ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA ...

The FDA has authorized ImmunityBio’s expanded access program to bring alternative sources of the cancer-fighting bacteria BCG ...

CONTINUED... Read this and more news for Oncolytics Biotech at: In other recent industry developments and happenings in the m ...